Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms (Q38112214)

29 August 2017

title

Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms (English)

1 reference

29 August 2017

1 reference

Makoto Naoi

1 reference

29 August 2017

Wakako Maruyama

series ordinal

1 reference

29 August 2017

Keiko Inaba-Hasegawa

series ordinal

1 reference

29 August 2017

publication date

1 June 2013

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

29 August 2017

published in

1 reference

29 August 2017

1 reference

29 August 2017

1 reference

29 August 2017

page(s)

671-684

1 reference

Parkinson's disease: mechanisms and models

29 August 2017

cites work

1 reference

21 January 2018

1 reference

Parkinson's disease: insights from pathways

21 January 2018

1 reference

Molecular pathways to neurodegeneration

21 January 2018

1 reference

The pathogenesis of cell death in Parkinson's disease

21 January 2018

1 reference

Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease

21 January 2018

1 reference

Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases

21 January 2018

1 reference

Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps

21 January 2018

1 reference

Developmental cell death: morphological diversity and multiple mechanisms

21 January 2018

1 reference

Apoptosis in Parkinson's disease: Is p53 the missing link between genetic and sporadic Parkinsonism?

21 January 2018

1 reference

The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease

21 January 2018

1 reference

Cell death mechanisms in neurodegeneration.

21 January 2018

1 reference

Apoptosis in Parkinson's disease: signals for neuronal degradation

21 January 2018

1 reference

Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology

21 January 2018

1 reference

Apoptosis-based therapies

21 January 2018

1 reference

Targeting programmed cell death in neurodegenerative diseases

21 January 2018

1 reference

New approaches and therapeutics targeting apoptosis in disease

21 January 2018

1 reference

Novel pharmacological targets for the treatment of Parkinson's disease

21 January 2018

1 reference

Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

21 January 2018

1 reference

Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor

21 January 2018

1 reference

Selegiline's neuroprotective capacity revisited

21 January 2018

1 reference

Pharmacological aspects of (-)-deprenyl

21 January 2018

1 reference

Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases

21 January 2018

1 reference

The therapeutic potential of monoamine oxidase inhibitors

21 January 2018

1 reference

Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders

21 January 2018

1 reference

Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease?

21 January 2018

1 reference

Perspectives on MAO-B in aging and neurological disease: where do we go from here?

21 January 2018

1 reference

MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology

21 January 2018

1 reference

Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells

21 January 2018

1 reference

Pro-apoptotic gene expression mediated by the p38 mitogen-activated protein kinase signal transduction pathway

21 January 2018

1 reference

Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway

21 January 2018

1 reference

Monoamine oxidase-A modulates apoptotic cell death induced by staurosporine in human neuroblastoma cells

21 January 2018

1 reference

A link between monoamine oxidase-A and apoptosis in serum deprived human SH-SY5Y neuroblastoma cells

21 January 2018

1 reference

N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor

21 January 2018

1 reference

Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase

21 January 2018

1 reference

''70th Birthday Professor Riederer'' induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (-)deprenyl: a way to a disease-modifying therapy?

21 January 2018

1 reference

Studies on the oxidation of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase B.

21 January 2018

1 reference

Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B.

21 January 2018

1 reference

Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline

21 January 2018

1 reference

Neuroprotective actions of Selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons

21 January 2018

1 reference

Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease

21 January 2018

1 reference

Immunohistochemical evidence of neuroprotection by R(-)-deprenyl and N-(2-hexyl)-N-methylpropargylamine on DSP-4-induced degeneration of rat brain noradrenergic axons and terminals

21 January 2018

1 reference

Deamination of 5-hydroxytryptamine by both forms of monoamine oxidase in the rat brain

21 January 2018

1 reference

Deprenyl reduces the death of motoneurons caused by axotomy

21 January 2018

1 reference

Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat.

21 January 2018

1 reference

Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat.

21 January 2018

1 reference

Rasagiline is neuroprotective in a transgenic model of multiple system atrophy

21 January 2018

1 reference

Dopamine-derived endogenous 1(R),2(N)-dimethyl-6,7-dihydroxy- 1,2,3,4-tetrahydroisoquinoline, N-methyl-(R)-salsolinol, induced parkinsonism in rat: biochemical, pathological and behavioral studies

21 January 2018

1 reference

Enantio-specific induction of apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine

21 January 2018

1 reference

Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol

21 January 2018

1 reference

Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan

21 January 2018

1 reference

The pathophysiology of mitochondrial cell death

21 January 2018

1 reference

Mitochondrial membrane permeabilization in cell death

21 January 2018

1 reference

A tale of two mitochondrial channels, MAC and PTP, in apoptosis

21 January 2018

1 reference

Mitochondrial membrane permeabilization in neuronal injury

21 January 2018

1 reference

Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate translocator display properties of the permeability transition pore. Implication for regulation of permeability transition by the kinases

21 January 2018

1 reference

The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis

21 January 2018

1 reference

Is mPTP the gatekeeper for necrosis, apoptosis, or both?

21 January 2018

1 reference

Regulation of the inner membrane mitochondrial permeability transition by the outer membrane translocator protein (peripheral benzodiazepine receptor)

21 January 2018

1 reference

VDAC regulation by the Bcl-2 family of proteins

21 January 2018

1 reference

Effect of R-(-)-deprenyl and harmaline on dopamine- and peroxynitrite-induced membrane permeability transition in brain mitochondria

21 January 2018

1 reference

Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline.

21 January 2018

1 reference

Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes

21 January 2018

1 reference

Targeting post-mitochondrial effectors of apoptosis for neuroprotection

21 January 2018

1 reference

Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism for better neuroprotective effects of allopregnanolone over progesterone

21 January 2018

1 reference

Inhibition of mitochondrial neural cell death pathways by protein transduction of Bcl-2 family proteins

21 January 2018

1 reference

Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease

21 January 2018

1 reference

Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness

21 January 2018

1 reference

Hydroxyl and peroxyl radical trapping by the monoamine oxidase-B inhibitors deprenyl and MDL 72,974A: implications for protection of biological substrates

21 January 2018

1 reference

Why (--)deprenyl prolongs survivals of experimental animals: increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects

21 January 2018

1 reference

21 January 2018

1 reference

Role of the redox protein thioredoxin in cytoprotective mechanism evoked by (-)-deprenyl

21 January 2018

1 reference

A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage

21 January 2018

1 reference

Neuroprotection by pharmacologic blockade of the GAPDH death cascade

21 January 2018

1 reference

Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan

21 January 2018

1 reference

Regulation of neuronal cell death and neurodegeneration by members of the Bcl-2 family: therapeutic implications

21 January 2018

1 reference

BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death

21 January 2018

1 reference

Long-term in vivo inhibition of CNS neurodegeneration by Bcl-XL gene transfer

21 January 2018

1 reference

Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity

21 January 2018

1 reference

Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration

21 January 2018

1 reference

Liposome-mediated transfer of the bcl-2 gene results in neuroprotection after in vivo transient focal cerebral ischemia in an animal model.

21 January 2018

1 reference

Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked

21 January 2018

1 reference

Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival

21 January 2018

1 reference

Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular-regulated kinase pathway

21 January 2018

1 reference

N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2.

21 January 2018

1 reference

Increased stress response and β–phenylethylamine in MAOB–deficient mice

21 January 2018

1 reference

Is there a "non-MAO" macromolecular target for L-deprenyl?: Studies on MAOB mutant mice

21 January 2018

1 reference

Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein.

21 January 2018

1 reference

Cyclic AMP-responsive element binding protein in brain mitochondria

21 January 2018

1 reference

Mitochondrial cyclic AMP response element-binding protein (CREB) mediates mitochondrial gene expression and neuronal survival

21 January 2018

1 reference

6-Hydroxydopamine induces mitochondrial ERK activation.

21 January 2018

1 reference

Regulation of MAO-A and MAO-B gene expression

21 January 2018

1 reference

Transcriptional regulation and multiple functions of MAO genes

21 January 2018

1 reference

Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1

21 January 2018

1 reference

Calcium alters monoamine oxidase-A parameters in human cerebellar and rat glial C6 cell extracts: possible influence by distinct signalling pathways

21 January 2018

1 reference

Valproic acid induces monoamine oxidase A via Akt/forkhead box O1 activation

21 January 2018

1 reference

Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells

21 January 2018

1 reference

Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues

21 January 2018

1 reference

Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis

21 January 2018

1 reference

Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice

21 January 2018

1 reference

I1 imidazoline receptor: novel potential cytoprotective target of TVP1022, the S-enantiomer of rasagiline

21 January 2018

1 reference

Occurrence risk and structure of depression in Parkinson disease with and without dementia: results from the GEPAD Study.

21 January 2018

1 reference

MAO-inhibitors in Parkinson's Disease

21 January 2018

1 reference

Neurotrophin-regulated signalling pathways

21 January 2018

1 reference

Absolute requirement of GDNF for adult catecholaminergic neuron survival

21 January 2018

1 reference

Neurotrophic factor therapy for Parkinson’s disease

21 January 2018

1 reference

Neurotrophins and cell death.

21 January 2018

1 reference

The GDNF family: signalling, biological functions and therapeutic value

21 January 2018

1 reference

GDNF and GFRalpha: a versatile molecular complex for developing neurons

21 January 2018

1 reference

Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain

21 January 2018

1 reference

Dopaminergic neurons protected from degeneration by GDNF gene therapy

21 January 2018

1 reference

Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease

21 January 2018

1 reference

GDNF and protection of adult central catecholaminergic neurons

21 January 2018

1 reference

Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult

21 January 2018

1 reference

Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease

21 January 2018

1 reference

Transgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell line-derived neurotrophic factor

21 January 2018

1 reference

Anterograde axonal transport of AAV2-GDNF in rat basal ganglia

21 January 2018

1 reference

Localized striatal delivery of GDNF as a treatment for Parkinson disease

21 January 2018

1 reference

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

21 January 2018

1 reference

GDNF therapy for Parkinson's disease

21 January 2018

1 reference

Repairing the parkinsonian brain with neurotrophic factors

21 January 2018

1 reference

Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal

21 January 2018

1 reference

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

21 January 2018

1 reference

Driving GDNF expression: the green and the red traffic lights

21 January 2018

1 reference

Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy

21 January 2018

1 reference

Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes

21 January 2018

1 reference

Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway

21 January 2018

1 reference

Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism

21 January 2018

1 reference

Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra

21 January 2018

1 reference

Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo

21 January 2018

1 reference

Trophic effects of selegiline on cultured dopaminergic neurons

21 January 2018

1 reference

Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications

21 January 2018

1 reference

The molecular neurobiology of depression

21 January 2018

1 reference

Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments

21 January 2018

1 reference

Antiapoptotic and neurotrophic effects of antidepressants: a review of clinical and experimental studies

21 January 2018

1 reference

Chronic administration of mood stabilizers upregulates BDNF and bcl-2 expression levels in rat frontal cortex

21 January 2018

1 reference

Neuroprotection by rasagiline in thiamine deficient rats

21 January 2018

1 reference

Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis

21 January 2018

1 reference

Monoamine oxidase: from genes to behavior

21 January 2018

1 reference

Topological Probes of Monoamine Oxidases A and B in Rat Liver Mitochondria: Inhibition by TEMPO-Substituted Pargyline Analogues and Inactivation by Proteolysis

21 January 2018

1 reference

Reactive astrocytes of the quinolinic acid-lesioned rat striatum express GFRalpha1 as well as GDNF in vivo

21 January 2018

1 reference

Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis

21 January 2018

1 reference

Six1 and Six4 are essential for Gdnf expression in the metanephric mesenchyme and ureteric bud formation, while Six1 deficiency alone causes mesonephric-tubule defects

21 January 2018

1 reference

Hox11 paralogous genes are essential for metanephric kidney induction

21 January 2018

1 reference

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

21 January 2018

1 reference

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients

21 January 2018

1 reference

Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?

21 January 2018

1 reference

Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline

21 January 2018

1 reference

Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro

21 January 2018

1 reference

An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group

21 January 2018

1 reference

What is the clinical significance of the findings from the delayed-start trial of rasagiline in Parkinson's disease?

21 January 2018

1 reference

Delayed start, rapid solution?

21 January 2018

1 reference

Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?

21 January 2018

1 reference

Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERN.13.60

1 reference

29 August 2017

1 reference